[Molecular diagnostics enable targeted therapies for anaplastic and poorly differentiated thyroid cancer]. / Molekylär diagnostik ger bättre behandling av tyreoideacancer.
Lakartidningen
; 1212024 Feb 27.
Article
de Sv
| MEDLINE
| ID: mdl-38712675
ABSTRACT
Anaplastic and poorly differentiated thyroid cancer (ATC, PDTC) are rare and highly aggressive tumors that historically have been associated with a short life expectancy and low chance of cure. Molecular pathology and the introduction of highly effective targeted drugs have revolutionized the possibilities of management of patients with ATC and PDTC, with BRAF and MEK inhibitors as the most prominent example. Here we provide updated recommendations regarding diagnostics and management, including primary surgical management and targeted therapies based on specific molecular pathological findings.
Recherche sur Google
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs de la thyroïde
/
Protéines proto-oncogènes B-raf
/
Thérapie moléculaire ciblée
/
Carcinome anaplasique de la thyroïde
Limites:
Humans
Langue:
Sv
Journal:
Lakartidningen
Année:
2024
Type de document:
Article
Pays de publication:
Suède